Levonorgestrel-releasing intrauterine device in the treatment of abnormal uterine bleeding: a 6- and 12-month morphological and clinical follow-up

Vittorio Palmara, Emanuele Sturlese, Daniela Villari, Valentina Giacobbe, Annalisa Retto, Giuseppe Santoro
The Australian & New Zealand journal of obstetrics & gynaecology · 2013 · vol. 53(4) , pp. 381–385 · doi:10.1111/ajo.12097 · PMID:23701372 · W2114420320
Non-randomised trial OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This study evaluated a levonorgestrel intrauterine device in women with abnormal uterine bleeding, finding it reduced endometrial thickness and bleeding while improving quality of life at 6 and 12 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Abnormal uterine bleeding is defined as any alteration in the pattern or volume of menstrual blood flow, and it is preferably treated using hysterectomy, endometrial destruction or the levonorgestrel-releasing intrauterine system (Mirena(®) ). Recently, it has been demonstrated that studies of Mirena(®) were generally small and consequently imprecise. AIMS: Our study was aimed at assessing the effects of a slow-release levonorgestrel (20 μg/day) intrauterine device in fertile and postmenopausal women experiencing abnormal uterine bleeding that did not respond to traditional medical management. MATERIALS AND METHODS: A total of 40 women, of whom 24 were of reproductive capacity and 16 were postmenopausal, were enrolled in the trial. Removal of the intrauterine device was required for only 2 of the 24 fertile women and for only 3 of the 16 postmenopausal women. After 6 and 12 months of treatment, the remaining women were clinically evaluated and underwent ultrasound and hysteroscopy using biopsy specimens as a control. The EuroQol Group EQ-5D questionnaire was used for evaluation of quality of life. RESULTS: The device showed good tolerability and efficacy. It resulted in a reduction in the endometrial mucosal thickness with a regression of bleeding and collateral effects, which were more evident after 12 months of treatment. A positive effect of the device on the woman's quality of life was demonstrated. CONCLUSIONS: The slow-release levonorgestrel intrauterine device may be a valid therapeutic tool for treating basic symptomatology and increasing quality of life in women with abnormal uterine bleeding.

My notes (saved in your browser only)

MeSH descriptors

Endometrial Hyperplasia Endometrium Intrauterine Devices, Medicated Levonorgestrel Metrorrhagia Adult Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Hyperplasia Endometrium Endometrium Endometrium Female Follow-Up Studies Humans Hysteroscopy Levonorgestrel Metrorrhagia Metrorrhagia Metrorrhagia

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (35)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-11T03:24:24.783323+00:00
pubmed
last seen: 2026-10-08T21:11:59.585523+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK